Aripiprazole in Schizophrenia Patients With Comorbid Obsessive-Compulsive Symptoms

Glick, Ira D.; Poyurovsky, Michael; Ivanova, Oxana; Koran, Lorrin M.

doi:10.4088/jcp.v69n1202

Cited by 49 publications

(17 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Chanachev et al reported on two cases in which augmentation with aripiprazole had a beneficial impact on anxiety [16]. In a study examining aripiprazole treatment in patients with comorbid schizophrenia and OCS that did not meet the full criteria for obsessive-compulsive disorder, results suggest that aripiprazole monotherapy can modestly improve the outcome for some schizophrenia patients with obsessive-compulsive symptoms [17]. In a case study, a patient with paranoid schizophrenia developed OCS during long-term treatment with olanzapine at 20 mg/day over a period of 10 years.…”

Section: Discussionmentioning

confidence: 99%

Aripirazole augmentation in clozapine-associated obsessive-compulsive symptoms in schizophrenia

et al. 2013

View full text Add to dashboard Cite

ObjectivePatients with schizophrenia often experience comorbid obsessive-compulsive symptoms. Within these patients, a significant subgroup developed secondary obsessive-compulsive symptoms during treatment with clozapine.MethodIn this paper, we report on four cases in which adjunctive therapy with aripiprazole was tested to alleviate obsessive-compulsive symptoms in schizophrenia.ResultsAll four patients had a significant improvement in obsessive-compulsive symptoms. The combination of clozapine and aripiprazole was well tolerated.ConclusionThis case series demonstrates the clinical efficacy of aripiprazole adjunctive therapy with clozapine in schizophrenic patients with comorbid obsessive-compulsive symptoms. Larger-sampled and controlled studies are required in order to test and confirm these observations.

show abstract

Section: Discussionmentioning

confidence: 99%

Aripirazole augmentation in clozapine-associated obsessive-compulsive symptoms in schizophrenia

et al. 2013

View full text Add to dashboard Cite

show abstract

“…Some studies suggest a role for aripiprazole in the treatment of OCD. These reports include aripiprazole augmentation of SRI in treatment-resistant OCD, or in patients with schizophrenia comorbid OCS (Glick et al, 2008; Arbaizar et al, 2009; McIntyre, 2010). …”

Section: Methodsmentioning

confidence: 99%

“…However, interesting data are emerging from the use of aripiprazole (the atypical antipsychotic with the higher D 2 – receptor affinity) and lamotrigine (an anticonvulsant inhibiting glutamate release). Glick et al (2008) conducted an open-label 6 week trial of aripiprazole monotherapy in 15 schizophrenic patients presenting OCS. Each patient switched from the ongoing antipsychotic medication to aripiprazole monotherapy.…”

Section: Methodsmentioning

confidence: 99%

Obsessive–Compulsive Disorder Comorbidity: Clinical Assessment and Therapeutic Implications

Pallanti¹,

Grassi²,

Sarrecchia³

et al. 2011

Front. Psychiatry

107

View full text Add to dashboard Cite

Obsessive–compulsive disorder (OCD) is a neuropsychiatric disorder affecting approximately 1–3% of the population. OCD is probably an etiologically heterogeneous condition. Individuals with OCD frequently have additional psychiatric disorders concomitantly or at some time during their lifetime. Recently, some authors proposed an OCD sub-classification based on comorbidity. An important issue in assessing comorbidity is the fact that the non-response to treatment often involves the presence of comorbid conditions. Non-responsive patients are more likely to meet criteria for comorbid axis I or axis II disorders and the presence of a specific comorbid condition could be a distinguishing feature in OCD, with influence on the treatment adequacy and outcome.

show abstract

“…Clinical efficacy of aripiprazole was observed for the treatment of comorbid obsessive compulsive symptoms in bipolar patients [19], schizophrenics [20] or in children with Tic Disorders [21]. In OCD patients resistant to conventional treatments, aripiprazole’s efficacy was first assessed as a monotherapy treatment in an open-label pilot trial [22].…”

Section: Introductionmentioning

confidence: 99%

Aripiprazole Augmentation in Patients with Resistant Obsessive Compulsive Disorder: a Pilot Study

Chiaie

Scarciglia

Pasquini

et al. 2011

CPEMH

View full text Add to dashboard Cite

Background:Antipsychotic augmentation is an effective treatment intervention for Obsessive Compulsive Disorder (OCD) patients resistant to Selective Serotonin Reuptake Inhibitors (SSRI) agents. This pilot study was conducted to evaluate the effectiveness and tolerability of Aripiprazole for the augmentation of standard treatments in patients with resistant OCD.Methods:Twenty patients diagnosed with OCD according to DSM-IV TR criteria and having a history of resistance to standard pharmacological treatment were included in the study. Aripiprazole was added to ongoing SSRI or clomipramine treatment with a starting dose of 5 mg/day and titrated up to a maximum of 20 mg/day (mean dose 12.62 mg ± 4.25). Efficacy was assessed with the Yale-Brown obsessive compulsive scale (Y-BOCS) and the Clinical Global Improvement-severity scale (CGI-S) at baseline and at week 12 of Aripiprazole augmentation. Side effects were monitored by the Udvalg for Kliniske Undersogelser (UKU) side effect rating scale.Results:All 20 subjects enrolled in our study completed the full 12-week course of treatment. A significant improvement over the 12-week study period was observed (paired t-test for mean Y-BOCS total score at week 12 as compared with baseline – all patients: t = 13.146, d.f. = 19, p= 0.0001). Aripiprazole was generally well tolerated and no changes were observed in vital signs. The most commonly observed side effects after the introduction of the augmenting agent included: akathysia, nausea/vomiting, hyperkinesia, tension/inner unrest, tremors, asthenia/lassitude/increased fatiguability. Conclusions:Although results of this pilot study are preliminary and require confirmation in randomized controlled trials, our experience suggested that Aripiprazole is effective and well-tolerated as an augmenting agent in patients with treatment resistant OCD.

show abstract

Aripiprazole in Schizophrenia Patients With Comorbid Obsessive-Compulsive Symptoms

Cited by 49 publications

References 0 publications

Aripirazole augmentation in clozapine-associated obsessive-compulsive symptoms in schizophrenia

Aripirazole augmentation in clozapine-associated obsessive-compulsive symptoms in schizophrenia

Obsessive–Compulsive Disorder Comorbidity: Clinical Assessment and Therapeutic Implications

Aripiprazole Augmentation in Patients with Resistant Obsessive Compulsive Disorder: a Pilot Study

Contact Info

Product

Resources

About